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In-silico insights on the prognostic 
potential of immune cell infiltration 
patterns in the breast lobular 
epithelium
J. C. L. Alfonso1,2, N. S. Schaadt3, R. Schönmeyer4, N. Brieu4, G. Forestier5,6, C. Wemmert5, 
F. Feuerhake3,7 & H. Hatzikirou1,2
Scattered inflammatory cells are commonly observed in mammary gland tissue, most likely in 
response to normal cell turnover by proliferation and apoptosis, or as part of immunosurveillance. In 
contrast, lymphocytic lobulitis (LLO) is a recurrent inflammation pattern, characterized by lymphoid 
cells infiltrating lobular structures, that has been associated with increased familial breast cancer risk 
and immune responses to clinically manifest cancer. The mechanisms and pathogenic implications 
related to the inflammatory microenvironment in breast tissue are still poorly understood. Currently, 
the definition of inflammation is mainly descriptive, not allowing a clear distinction of LLO from 
physiological immunological responses and its role in oncogenesis remains unclear. To gain insights 
into the prognostic potential of inflammation, we developed an agent-based model of immune and 
epithelial cell interactions in breast lobular epithelium. Physiological parameters were calibrated 
from breast tissue samples of women who underwent reduction mammoplasty due to orthopedic or 
cosmetic reasons. The model allowed to investigate the impact of menstrual cycle length and hormone 
status on inflammatory responses to cell turnover in the breast tissue. Our findings suggested that 
the immunological context, defined by the immune cell density, functional orientation and spatial 
distribution, contains prognostic information previously not captured by conventional diagnostic 
approaches.
Several studies provided conclusive evidence that a delicate balance between mammary epithelial cell prolifer-
ation and apoptosis regulates homeostasis in the healthy breast tissue1–7. After menarche, and in the absence of 
pregnancy, the adult female mammary gland is subjected to cyclic fluctuations depending on hormonal stim-
ulation1,8. In response to such systemic hormonal changes, the breast epithelium undergoes a tightly regulated 
sequence of cell proliferation and apoptosis during each ovarian/menstrual cycle1–3. The peak of epithelial cell 
proliferation has been reported to occur during the luteal phase, suggesting a synergistic influence of steroid 
hormones, such as estrogen and progesterone2–5. In turn, the peak of apoptotic activity would be expected in 
response to decreasing hormone levels towards the end of the menstrual cycle2–5. However, recent histologic 
findings indicate that apoptosis reaches its maximum levels in the middle of the luteal phase, although there is 
also a peak at about the third day of the menstrual cycle6,7. Experimental measurements of cell turnover, i.e. pro-
grammed cell death and proliferation, demonstrated that an imbalance between the mitotic and apoptotic activity 
might lead to malignant transformation of epithelial cells and tumorigenic processes9–11. Indeed, excessive cell 
proliferation promotes accumulation of DNA damage due to insufficient timely repair and mutations12,13. There 
is also recent evidence that hormones suppress effective DNA repair and alter DNA damage response (DDR)13–15.
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Previous models of transgenic mice engineered to develop mammary cancer demonstrated that abnormal pat-
terns of cell turnover result in a higher risk of cancer development16. Moreover, genetic and epigenetic changes in 
genes that regulate mammary epithelial cell proliferation and apoptosis are considered possible initiators of breast 
carcinogenesis17,18. In fact, each cell in the human body faces everyday environmental challenges (e.g. ultraviolet 
light (UV) and terrestrial irradiation) that lead to DNA lesions that are constantly being repaired19. In addition 
to these exogenous agents, a mechanism particularly susceptible to DNA damage is DNA replication during cell 
division. Protection against DNA aberrations, arising via such physiological processes as DNA mismatches, is 
provided particularly by the BRCA1/2 breast cancer susceptibility genes, which are crucial to avoid double-strand 
DNA damage during cell mitosis20,21. Mutations within BRCA1 and BRCA2 imply a high lifetime risk of devel-
oping carcinoma and account for most cases of familial breast cancers21,22. Experimental observations suggested 
that increased DNA damage levels and DNA repair defects are associated with an elevated risk of breast cancer23. 
Indeed, it is known that the development of tumors is associated with accumulation of DNA mutations in somatic 
cells24–26. Thus, mechanisms indicating failure to eliminate damaged epithelial cells may be equally promising 
candidates for novel breast cancer risk biomarkers as markers of DNA repair defects.
In the healthy breast tissue, lymphocytes are present and mainly localized within lobules rather than interlob-
ular stroma27, with T-cells directly integrated in the lobular epithelium as part of the immune system (Figs 1 and 2 
and Supplemental Fig. S5). There is strong evidence from murine models that immune cells carry out surveil-
lance against infections and can eradicate nascent transformed cells before they grow into tumors28,29, indicating 
that the immune system plays a crucial role in maintaining the mammary gland function27,30. However, most of 
the factors and mechanisms that regulate the inflammatory microenvironment in the breast lobular epithelium 
Figure 1. The range of infiltration patterns within breast tissue from one healthy woman. From top 
to bottom, immunohistochemical stainings for CD8, CD163 and CD4. From left to right, a representative 
spectrum of immune cell infiltration in different lobular structures for almost consecutive tissue sections 
by columns. The breast tissue samples were obtained from reduction mammoplasty in a 25-year-old 
premenopausal woman without clinical abnormality nor familial history of breast cancer, who underwent the 
surgical procedure during the luteal phase of her regular menstrual cycle, reported to be 30 days long.
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are only partly understood27. In particular, those related to lymphocytic lobulitis (LLO), a characteristic pattern 
of inflammation frequently observed in non-neoplastic lobular structures adjacent to hereditary breast cancer, 
as well as in prophylactically removed breast tissue from patients without and with cancer-predisposing germ 
line aberrations BRCA1/227,31–35. LLO has been defined based on estimates of immune cell number per lobule 
on hematoxylin and eosin (H&E) stainings. While some authors proposed a criterion of > 100 lymphocytes per 
lobule33, others considered estimates of > 50 lymphocytes per lobule for moderate and > 100 lymphocytes per 
lobule for marked lobulitis35. However, the anatomical term lobule as a reference region for immune cell counting 
is prone to uncertainties due to variable shapes and sizes with respect to the number of epithelial cells8. Although 
LLO in non-neoplastic breast tissue has been recently associated with clinicopathologic features more commonly 
observed in hereditary breast cancer33,35, the biological and functional role of such inflammatory pattern in the 
normal lobular epithelium is unclear and the prognostic potential in the promotion of breast carcinomas remains 
to be elucidated. Figures 1 and 2 illustrate the full range of inflammatory patterns of CD8+, CD4+ and CD163+ 
cells observed within breast tissue from one individual healthy woman (Fig. 1) and across several healthy women 
(Fig. 2). Note the impressive heterogeneity within individuals and across different samples, and that even in the 
normal breast tissue, some lobules formally had to be assigned to LLO if any of the previous definitions would be 
consequently applied.
Accumulated experimental and clinical data indicate that the development of breast cancer is associated with 
a significant increase, and characteristic patterning, of both innate and adaptive immune cells36. In particular, 
T-lymphocytes and macrophages have been reported as the most abundant leukocytes present in neoplastic 
Figure 2. The range of infiltration patterns across breast tissue samples from several healthy women. From 
top to bottom, immunohistochemical stainings for CD8, CD163 and CD4. From left to right, a representative 
spectrum of immune cell infiltration in different lobular structures for almost consecutive tissue sections by 
columns. The breast tissue samples show representative variations as observed in premenopausal women 
without clinical abnormality nor familial history of breast cancer, with ages ranging from 20 to 33 years (median 
age 24.5 years), who underwent the surgical procedures during the luteal phase of their regular menstrual 
cycles, reported to be from 25 to 37 days long (median 28 days).
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stroma. Furthermore, T-lymphocytes are also commonly associated with the development of breast cancer36, as 
well as macrophages that can influence growth, survival and invasion of tumor cells, angiogenesis and inhibition 
of cytotoxic T-cell responses which contributes to cancer immune evasion37. Additionally, during inflammatory 
responses certain types of macrophages produce a wide array of compounds that are likely to contribute to can-
cer initiation38. Previous findings led to the hypothesis that LLO could potentially be linked to pre-malignant 
precursor lesions or be associated with inherited breast cancer27,33,35. Indeed, the general functional relation-
ship between inflammation and cancer has been extensively investigated39–41 and there is strong evidence from 
some cancer types that sustained cell proliferation in an environment rich in inflammatory immune cells and 
DNA damage promoting agents certainly potentiates neoplastic risk24,26,41,42. Considering these facts, the associ-
ated immune responses to few aberrant cells in breast tissue, that may give rise to malignancies due to impaired 
DNA-repair mechanisms by BRCA1/2 mutations, may potentially be driving the earliest stages of cancer devel-
opment. Therefore, a dynamic understanding of these early events is a crucial step towards investigating the 
prognostic role of inflammation in the breast lobular tissue.
For this purpose, we develop a cell-based model of epithelial and immune cell interactions in the breast lob-
ular epithelium during the menstrual cycle. We use a novel approach that models immune system dynamics 
linked to the regular cyclic changes influenced by hormones of epithelial cell turnover in the breast tissue. The 
aim is to interpret snapshot-like single time points of breast tissue samples in the context of a mathematical model 
by considering crucial aspects of the underlying dynamic processes. Beyond the mechanistic understanding, 
we intend to generate insights into the functional and prognostic role of inflammation. Physiological model 
parameters are calibrated on the basis of data extracted from digital whole-slide images of immunohistochemical 
epithelial, vascular and immune cell markers on clinical annotation from a cohort of non-neoplastic women who 
underwent reduction mammoplasty due to orthopedic or cosmetic indications. Initially, we investigate recurrent 
inflammation during physiological menstrual cycles and normal hormone levels. Then, we systematically analyze 
parameter perturbations that may potentially lead to oncogenic events. In particular, we qualitatively analyze 
lobular inflammation patterns under systematic variation of model parameters, such as increased epithelial cell 
turnover rates influenced by different hormone levels, length of the menstrual cycle, impaired DNA-repair mech-
anisms due to BRCA1/2 mutations and cytotoxic immune responses. Model results suggest that immune infiltrate 
spatial patterns and integration of personalized clinical data in the process of interpreting image-based findings 
could contribute to the extension of criteria for biopsy evaluation and development of novel prognostic markers.
Material and Methods
Experimental data. We consider breast tissue samples from a cohort of 22 healthy women, with ages rang-
ing from 21 to 53 years (median age 30.5 years), who underwent reduction mammoplasty due to orthopedic or 
cosmetic indications43. The breast tissue samples were obtained during surgical procedures. Patients were not 
taking any oral contraceptives at the time of surgery. They were all premenopausal women without clinical abnor-
mality nor familial history of breast cancer. Relevant co-morbidity, in particular autoimmune diseases including 
type I diabetes mellitus (T1DM), was not reported by any patient. Moreover, no clinical or radiological signs of 
breast lesions were reported in the clinical records. The phases of the menstrual cycle were determined by anam-
nestic documentation of the menses prior to the surgical intervention and complemented by asking the patients 
to report the date of onset of their first menstruation after surgery. Menstrual cycles range from 25 to 38 days, 
with 10 patients having a cycle length of 28 days (Supplemental Table S1). Patients were divided into luteal phase 
from 0–11 days between the surgery time and onset of menses afterwards, and into follicular phase from 17–30 
days between both dates avoiding uncertainties during mid cycle (Supplemental Table S2). This dataset is used to 
calibrate the model parameters during physiological homeostasis.
The formalin-fixed and paraffin-embedded breast tissues were cut in sections of 3 μm thickness. 
Immunohistochemistry was performed to stain for cytotoxic T-lymphocytes (CD8; Dako M7103), regulatory 
T-cells (CD4; Zytomed Systems 503-3354) and macrophages (CD163; medac diagnostika 163M-16) on an auto-
mated instrument (Ventana Benchmark Ultra). Quantification of epithelial and immune cells was performed in 
about 650 (luteal phase) and 250 (follicular phase) representative breast lobular structures with between 250 and 
2500 epithelial cells in whole slide images by means of an automated image analysis workflow. More precisely, a 
module for automated detection of single cells and nuclei from the Definiens Tissue Phenomics framework was 
used, which is based on the Definiens Image Miner and Developer Software44. The healthy women in our cohort 
were all adult at the time of the surgical procedure. Thus, we assumed that the adult breast is not growing and the 
epithelial compartment of mammary gland is only subject to a normal, overall balanced cell turnover/renewal 
at each menstrual cycle. In the following, the amount of immune cells is provided with respect to the number 
of epithelial cells and referred to as relative number. Figure 3a–c shows the resulting epithelial and immune cell 
quantification in normal breast tissue samples with respect to the follicular and luteal menstrual cycle phases 
(Supplemental Fig. S6).
We further consider a “proof-of-principle” dataset consisting of breast tissue samples obtained during surgical 
procedures from (i) 7 premenopausal healthy women who underwent reduction mammoplasty (RM) without 
clinical abnormality nor familial history of breast cancer, ages ranging from 21 to 45 years (median age 32 years), 
(ii) 21 premenopausal women who underwent prophylactic mastectomy (PM) due to an increased risk of hered-
itary breast cancer (BRCA1/2 mutations) without clinical or pathological abnormalities, ages ranging from 22 
to 53 years (median age 38 years), and (iii) a cohort of 7 premenopausal women with clinically manifest breast 
cancer, ages ranging from 30 to 43 years (median age 41 years). No details about the menstrual cycle phase were 
reported in the clinical records as it is not routinely collected. This serie of breast tissue samples is considered as a 
validation set of the model-based inflammatory pattern predictions.
The research was carried out in accordance with all relevant laws, guidelines and regulations. Experimental 
protocols including research use of surplus diagnostic materials were approved by the local institutional review 
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board (Ethics Commission of Hannover Medical School; vote #2063-2013). Informed consent from patients was 
obtained from all subjects.
A multiscale model of immune cell infiltration in breast lobular epithelium. We develop a mul-
tiscale agent-based model of epithelial and immune cell interactions in the breast lobular epithelium. Each cell 
is individually represented and its fate is determined by mechanistic rules and microenvironmental cues. In the 
following, we summarize the main model assumptions and experimental data-based parameterization (see the 
Supporting Information for further details).
Breast lobular epithelium geometry and cell types. The model accounts for myoepithelial and luminal cells that 
comprise the breast lobular epithelium. The human mammary gland constitutes a branching ductal-lobular sys-
tem composed of an inner layer of polarized luminal cells and an outer layer of myoepithelial cells8. The luminal 
lineage contains polarized cells that line the lumina of mammary ducts which may contain secretory material. 
In turn, myoepithelial cells are localized between luminal cells and intralobular stroma, which positions them 
to communicate with both compartments45. These cellular layers are separated from the collagenous interstitial 
stroma by a basement membrane, which is not a limitation for immune cell movement (Supplemental Fig. S5)8,46. 
The breast stroma is made up of collagen and fibroblasts, interlobular dense fibro connective tissue, intralobu-
lar loose connective tissue and blood vessels8,46–48. This ductal network terminates in lobular units, commonly 
referred to as terminal duct lobular units (TDLUs), composed by lobules that are formed from tubular epithelial 
structures8,46.
Immune cells are crucially involved in maintaining the mammary gland function30,49. Lymphocytes are pres-
ent and mainly localized to lobular structures rather than in the interlobular stroma, with T-cells directly inte-
grated into the epithelium as part of the immune system (Supplemental Fig. S5f)27. Among the main immune 
components in the breast lobular tissue are the effector/regulatory T-cells and monocyte/macrophages27. In par-
ticular, CD4+ cells, CD163+ macrophages and CD8+ T-lymphocytes have been reported to be present in the 
breast tissue lobules with and without lobulitis (Supplemental Figs S8, S10 and S11)27, as well as involved in sev-
eral cancer-related processes50. Cytotoxic CD8+ T-lymphocytes (CTLs) have the potential to kill several damaged 
cells by direct contact, indicating that they may recycle from one target to another and makes them very efficient 
effector cells51,52. It is known that (effector) CD8+ T-cells carry out their killing function by releasing cytotoxic 
proteins, which activates an endogenous apoptotic pathway within the target cells53,54. Besides many other func-
tions, both CD4+ T-cells and CD163+ macrophages can suppress the cytotoxic responses of effectors resembling 
Figure 3. Experimental data, agent-based model simulation domain and epithelial cell turnover during 
the menstrual cycle. (a–c) Quantification of epithelial and immune cells in breast lobular tissue. From left to 
right, amount of epithelial cells and relative number of (a) CD8+, (b) CD163+ and (c) CD4+ cells with respect to 
the menstrual cycle phase in healthy women. Each box is drawn around the region between the first and third 
quartiles of the data points, with a horizontal line at the median value and whiskers extend for a range equal to 
1.5 times the interquartile range. (d,e) Cross-sections of terminal ductal lobular units (TDLUs). (d) Annotated 
TDLUs composed by several terminal ductules/acini and (e) the corresponding simplified simulation domain, 
where luminal (light blue) and myoepithelial (dark blue) cells are represented, respectively. (f) Normalized 
curves of the epithelial cell proliferation (PI) and apoptosis (AI) indices with respect to the menstrual cycle. The 
follicular phase ranges from day 0 to 14, while the luteal phase between days 14 and 28.
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the function of regulatory cells55–59. The scavenger receptor CD163 is considered as a highly specific monocyte/
macrophage marker for alternatively activated macrophages, often referred to as “M2” phenotype, with the poten-
tial to mediate anti-inflammatory effects55. These CD163+ myeloid derived cells could be suppressor cells that 
have been reported with an immunosuppressive effect on effector-dependent responses55–57. In turn, subsets of 
CD4+ T-helper cells have also the potential to suppress the cytotoxic responses of CD8+ T-cells, which is a key 
component of antitumor immunity58,59. Accordingly, we assume in a simplified strongly approach that, while 
effector CD8+ cells are the only responsible for killing (target) damaged epithelial cells, the function of regulatory 
CD4+ and CD163+ cells is a general suppression of effector-dependent responses by inducing inactivation.
The simulation domain represents cross-sections of terminal ductal lobular units (TDLUs) composed by 
several terminal ductules/acini, each with an inner layer of luminal cells surrounded by an exterior layer of 
myoepithelial cells. A cross-section of a TDLU is defined by a polygon delimiting the intra- and interlobular 
stroma (Fig. 3d,e). The separation between the inter- and intralobular stroma is based on stainings of Collagen IV 
(Supplemental Fig. S5), as well as on the annotations usually performed by pathologists during tissue biopsy 
evaluation. This clear separation between the lobular tissue and intralobular stroma is also supported by stainings 
of CD8, CD163 and CD4, where we observe that positive cells are mainly located close to the breast epithelium 
(Supplemental Figs S8, S10 and S11). In the mammary gland, as well as in other epithelial structures, cells are 
polarized into apical and basal cell compartments, connected by physical bonds such as tight junctions. The 
basal membrane keeps epithelial cells neatly organized in their functional structure, clearly separated from the 
underlying connective and fat tissue8,46. Accordingly, luminal and myoepithelial cells are assumed firmly placed 
within the breast lobular epithelium. On the contrary, immune cells are motile and can be located everywhere in 
the intra- and interlobular stroma except into the lobular lumina8,46.
Cell states. We assume that epithelial cells could become aberrantly damaged by DNA repair defects, for 
instance due to BRCA1/2 mutations, that result in impaired DNA-double strand break repair mechanisms21,20. 
While epithelial cells dying by apoptosis (programmed death) would not pose any threat to the organism, dam-
aged cells may represent a risk for breast cancer and need to be actively eliminated by the immune system. In the 
model, we assume that epithelial cells may be either in a normal, damaged or dying state. Moreover, normally 
dying apoptotic cells send out chemotactic find-me signals, which recruit innate immune cells to verify that 
apoptosis is correctly accomplished and to induce the clearance of the resultant debris60–62. These find-me signals 
create local gradients that serves to bring nearby immune cells to the dying cell63. In turn, aberrantly damaged 
cells that are not yet cancer cells, but have the potential of malignant transformation (see hallmarks of cancer con-
cept24,26), are a source of chemotactic signals that attract and activate immune cells. Recent evidence indicates that 
the DDR signaling cascade influences the biology of the surrounding cellular microenvironment in a paracrine 
manner which induces an immune response64,65. This response to persistent DNA damage activates a variety of 
transcription factors that induce the expression of different immune genes including inflammatory cytokines 
and chemokines64,66,67. The damaged epithelial cells are seen as refusing to die quietly and need to be actively 
killed by effector cells before they can cause severe problems24,26. In particular, we assume that damaged and 
dying epithelial cells release two different chemokines (or chemotactic cytokines) inducing immune responses. 
Spatio-temporal dynamic of chemokine concentrations is modeled as a continuous field by a partial differential 
equation (see the Supporting Information for further details).
The chemotactic ability of cytokines is critical for the trafficking, homing and activation of leukocytes cru-
cial to the innate immune response68. In fact, inflammatory chemokines are known as potent leukocyte activa-
tors expressed in inflamed tissues, and are therefore mostly considered as pro-inflammatory mediators68–70. We 
assume that immune cells become activated by chemokines from damaged epithelial cells. On the other hand, 
activated immune cells become inactive in the absence of such chemoattractant signals or due to the suppressing 
action of regulatory cells in the case of effectors.
Cell processes. Figure 4a shows a schematic representation of the cell processes mimicked in the agent-based 
model, i.e. proliferation of epithelial cells, immune cell motility and trafficking, death of damaged epithelial cells 
by effectors, inactivation of effectors by regulatory cells, programmed cell death (apoptosis) and lysis (removal of 
cellular debris). Cellular processes are represented in the model by stochastic events at different rates depending 
on the cell type and internal state.
•	  Immune cell trafficking. Blood vessels are essential for trafficking of immune cells68,70. The stroma of the 
mammary gland is made up of fat tissue, interlobular dense fibro connective tissue, intralobular loose con-
nective tissue and blood vessels8,46–48. We assume that blood vessels are homogeneously distributed in the 
intra- and interlobular stroma (Supplemental Fig. S3). This assumption implies that immune cells can enter 
and leave the system from any node in the simulation domain.
  Lymphocyte traffic is mainly controlled by chemokines68–71. We assume that chemokines from damaged epi-
thelial cells influence the trafficking of both regulatory and effector cells, while chemokines from dying epi-
thelial cells only affect the trafficking of effector cells. The latter assumptions are based on our experimental 
observations. While in homeostasis the amount of (effector) CD8+ T-lymphocytes significantly change dur-
ing the menstrual cycle, the number of (regulatory) CD4+ and CD163+ cells can be considered that remains 
almost invariant (Fig. 3a–c).
•	 Motility. Immune cell movement is only limited to the lumina of the acini (Fig. 3d,e). Once out of the 
bloodstream, immune cells follow chemokine gradients by a process called chemotaxis, which allows them 
to reach sites of inflammation and during normal homing to lymphoid organs68–71. We assume that immune 
cells are subject to chemotactic movement in response to chemokines from damaged and dying epithelial 
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cells. On the other hand, immune cells are subject to random movement in the absence of chemoattractant 
signals.
•	 Immunosuppression. Activated regulatory cells permanently inactivate, by direct contact, effector cells at a 
certain rate. This rate increases proportionally with the number of activated regulatory cells surrounding an 
activated effector cell.
•	 Proliferation and Damage. Epithelial cells can divide at an intrinsic rate kpro, which results in a daughter cell 
that in turns can become aberrantly damaged at a rate kdge. Damaged epithelial cells can proliferate giving rise 
to an identical damaged daughter cell. Moreover, damaged epithelial cells never die due to apoptosis needing 
to be actively eliminated by effector cells, and produce a chemoattractant signal that induces the recruitment 
of immune cells. For simplicity, we assume that immune cells do not proliferate, and therefore their dynamic 
is exclusively characterized by motility and trafficking.
•	  Programmed cell death. Undamaged epithelial cells are subject to apoptosis at an intrinsic rate kapt. More-
over, we assume that damaged epithelial cells can only die by the cytotoxic action of activated effector cells.
•	 Induced cell death. Activated effector cells induce death, by direct contact, to damaged epithelial cells at a 
rate kkill. This rate increases proportionally with the number of activated effectors surrounding a target epi-
thelial cell.
•	 Lysis. Disposal of cellular debris resulting from apoptosis is carried out by a lysis process that removes dead 
epithelial cells from the model simulation domain.
Figure 4. Agent-based model formulation details. (a) Schematic representation of the cell processes 
mimicked in the agent-based model. (b) Flowchart describing the checkpoints and possible actions that cells 
can perform in each simulation time-step.
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Simulation flowchart and cell life cycle scheme. The flowchart in Fig. 4b shows how the accessible model states 
for the respective transition of a configuration of N cells are determined algorithmically in the simulations. Every 
cell includes a stochastic decision-making process that models phenotypic/state changes according to mechanis-
tic rules and microenvironmental cues. At each simulation time-step, cells are randomly selected for which an 
additional process to update cell states is also randomly executed to avoid any order bias. In the case of aberrantly 
damaged epithelial cells, a checkpoint for induction of death by activated effector cells is executed. Moreover, 
immune cells have a checkpoint for activation and inactivation. Effector cells can be permanently inactivated 
by direct contact with activated regulatory cells. After this update process, dying epithelial cells are subject to a 
lysis process inducing its removal from the lattice. Otherwise, undamaged epithelial cells in a node with no free 
neighbor nodes can die due to apoptosis. If there is a free node next to the selected cell, processes such as motility, 
proliferation and apoptosis are randomly selected until one is executed or all of them have been verified but not 
triggered. If motility is executed, the cell moves to a free neighbor node, while proliferation produces a daughter 
cell. This iterative process is executed until all cells have been updated in the current simulation time-step. At the 
end of each simulation time-step, immune cell populations are updated through an iterative process. In particular, 
immune cell trafficking is governed by rates depending on the intensity of chemokines from damaged and dying 
epithelial cells (see the Supporting Information for further details).
Parameter calibration. Assessments of epithelial cell proliferation and apoptosis in healthy human mammary 
tissue during the follicular and luteal phase of the menstrual cycle have been recently reported2–4,7. In particular, 
estimates of a proliferation (PI) and apoptotic (AI) index, defined as the number of Ki-67 and TUNEL positive 
cells per 1000 epithelial cells, were provided7. The highest PI value was detected near the end of the menstrual 
cycle, whereas the AI reached its maximum at the beginning and end of the menstrual cycle. The PI values were 
estimated between 30.46 (luteal phase) and 13.45 (follicular phase). The cell renewal index PI/AI was also signif-
icantly higher in the luteal phase of the menstrual cycle.
We consider normalized versions of the PI and AI curves with respect to the menstrual cycle7 to modulate the 
intrinsic proliferation kpro and apoptotic kapt rates of epithelial cells (Fig. 3f). This allows to reproduce the oscilla-
tions of cell turnover in the lobular epithelium during menstrual cycles and normal hormone levels. Assuming the 
physiological plausible proliferation rate of epithelial cells kpro = 0.03 h−1 72–74 and estimating the apoptotic rate as 
kapt = 0.0021 h−1, we can reproduce the PI = 30.5 ± 22 values measured experimentally during the menstrual cycle 
(Fig. 5). We remark that the interdependent mitotic and apoptotic events should be balanced in adult women to 
keep breast tissue homeostasis. However, TUNEL-positive cells only represent a small part of the total number of 
apoptotic cells, since only the final phases within the time course of apoptosis are labeled. The same holds true for 
other apoptosis markers such as cleaved caspase-3, a marker for a short part of the execution phase of apoptosis. 
Figure 5. Time evolution of epithelial and immune cells in healthy breast tissue. The results are averaged 
over 20 simulations each consisting in 12 menstrual cycles of 28 days and normal hormone levels. (a) Amount 
of epithelial cells. (b) Relative number of regulatory and effector cells. (c,d) Number of proliferating and 
apoptotic epithelial cells per 1000 epithelial cells, respectively. Simulation results for a single menstrual cycle are 
represented in the right panels.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:33322 | DOI: 10.1038/srep33322
Indeed, only few cells were stained by cleaved caspase-3 marker (Supplemental Fig. S5), and their overall number 
was lower than the amount of (mitotic) Ki-67 positive cells. This is due to the fact that only short phases within 
the time course of apoptosis are labeled, whereas Ki-67 stains all cycle phases except the resting cells in G0 phase. 
Thus, the amount of apoptotic epithelial cells is calibrated to balance the PI values experimentally quantified.
Physiological parameters related to immune cell trafficking are calibrated based on the experimental data in 
Fig. 3a–c. Figure 5 shows the resulting time evolution of epithelial and immune cells in healthy breast tissue dur-
ing several menstrual cycles. The mean relative number of effector cells in the follicular (day 1 to 11), in-between 
(days 11 to 17) and luteal (days 17 to 28) phases are 0.05 ± 0.01, 0.04 ± 0.01 and 0.07 ± 0.02, respectively. In turn, 
the mean relative number of regulatory cells during the menstrual cycle is 0.055 ± 0.01. The calibrated model 
parameters also provide accurate estimates of the relative number and spatial distribution of immune cells during 
the menstrual cycle (Supplemental Figs S6 and S7). We provide details in the Supporting Information about the 
immune cell trafficking implementation and estimation of the other model parameters.
Results
Due to the stochastic nature of the model, we performed for each parameter constellation 10 simulations each 
consisting of 12 menstrual cycles (about 1 year) and monitored the average statistics. The relative number of dam-
aged epithelial and immune cells are provided with respect to the total number of epithelial cells in the simulated 
cross-sections of TDLUs.
Existence of a critical damage rate of epithelial cells that determines different inflammatory 
regimes. We first investigate the inflammatory responses to different damage rates of epithelial cells kdge, a 
menstrual cycle of 28 days and normal hormone levels. Figure 6a–d shows the resulting epithelial damage and 
immune responses to increasing kdge values for different killing rates of damaged epithelial cells by effectors kkill. 
Model simulations predict that there exists a critical kdge value from which the relative number of damaged epithe-
lial cells increases non-linearly (Fig. 6a,b) and suppression of effector cell-dependent responses occurs (Fig. 6c,d). 
Below this critical threshold, epithelial damage scales linearly with kdge, which is associated with a tightly con-
trolled inflammation (Fig. 6a,b). On the other hand, higher kdge values result in stronger inflammatory responses 
with marked immunosuppression and epithelial cell damage. This may increase the risk of developing various 
breast pathologies, which may lead to oncogenic events. Figure 6a,b shows that such critical threshold depends 
on the effectiveness of the immune system to control epithelial cell abnormalities. When decreasing the killing 
rate kkill, the relative number of damaged epithelial and immune cells increases, and the resulting inflammatory 
responses exhibit stronger suppressive activity of regulatory cells to prevent pathological self-reactivity (compare 
Fig. 6c to 6d). Moreover, a decreased ability of effectors to kill target cells is predicted to contribute to immuno-
logical context heterogeneity in terms of the functional orientation of immune infiltrates (Fig. 6e). This suggests 
that not only the number of immune infiltrates, but also the functional orientation of the immune contexture, 
may be considered as a marker of epithelial damage.
Figure 6c,d shows high variations in the amount of immune infiltrates during the menstrual cycle when epi-
thelial cell damage is triggered, which may have a significant impact on tissue homeostasis. In particular, we 
assume that inflammatory responses are physiological as long as the amount of damaged epithelial cells increases 
Figure 6. Inflammatory responses induced by increasing damage rates of epithelial cells. The results are 
averaged over 10 simulations, for every parameter constellation, each consisting in 12 menstrual cycles of 28 
days and normal hormone levels. The mean (marked solid line) and min/max (shadow) values are represented. 
(a,b) Relative number of damaged epithelial cells for kkill = 0.05 and kkill = 0.10, respectively. (c,d) Relative 
number of immune cells for kkill = 0.05 and kkill = 0.10, respectively. (e) Difference between the relative number 
of regulatory and effector cells for different kkill values. (f) Relative number of immune cells during a single 
menstrual cycle for kkill = 0.05 and different kdge values.
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linearly with kdge (Fig. 6a,b). Working under this assumption, the maximum relative number of immune cells given by 
such critical damage rate, which separates physiological from pathological responses, allows to characterize at least two 
other inflammatory regimes. One regime of severe inflammations for intermediate damage rates and the other regime 
of chronic (persistent) inflammations for higher kdge values (Fig. 6c,d). While during chronic inflammatory responses 
immune cells never leave the breast lobular epithelium, for intermediate kdge values the resultant inflammation resolves. 
Figure 6f shows that a higher amount of infiltrating immune cells is more frequent at the beginning (days 0–7) and end 
(days 21–28) of the menstrual cycle than at the middle (days 7–21). Moreover, we found that for a range of kdge values, 
defining the regime of severe inflammations, there may be peaks of immune infiltrates closely resembling physiolog-
ical and pathological conditions during the menstrual cycle (Fig. 6f). This leads to misleading normal inflammatory 
responses that need to be recognized. These findings suggest that inflammatory responses are oscillatory phenomena 
that depend on the epithelial cell damage rate and menstrual cycle length.
Increased hormone levels enhance epithelial damage and inflammatory responses. To gain 
insights into the effect of hormonal changes on breast tissue damage and inflammatory responses, we modulate the 
normalized curves of epithelial cell proliferation and apoptosis during the menstrual cycle (Fig. 3f) by a positive scaling 
factor θ, i.e. referred to as the hormone level. By doing this, we assume that the hormonal status directly affects the cell 
turnover rate in the lobular epithelium1–3,20. Figure 7a shows different hormone-modulated sets of the normalized 
proliferation and apoptosis curves with respect to the menstrual cycle for θ = 0.05 and θ = 2.0. These values respectively 
correspond to decreased and increased hormone levels with respect to the normal status θ = 1.0.
Figure 7b shows that the relative number of immune cells in the breast lobular epithelium is predicted to 
increase linearly with rising hormone levels θ. We also found that irrespective of the hormonal status, when 
epithelial cell damage is triggered the amount of immune infiltrates significantly increases compared to phys-
iological conditions. This is particularly critical for high θ values, which strongly influence the epithelial cell 
turnover rate and give rise to large fluctuations in the associated inflammatory responses. Figure 7c shows that 
epithelial damage increases in more enriched hormonal milieu, as well as variations in the amount of immune 
infiltrates in the lobular tissue during the menstrual cycle (Fig. 7d). In turn, the suppressive action of regulatory 
cells to effector responses is more prominent in breast tissues with high hormone levels (Fig. 7e).
Epithelial damage induces clustering patterns of immune cells. Spatial distribution of immune 
cells is determined by the radial distribution function g(r) that describes how density varies as a function of 
the distance from a reference immune cell r75. The function g(r) is calculated at the follicular (day 5) and luteal 
(day 25) phase of the menstrual cycle, as well as in the middle (day 14). We then consider the mean g(r) values 
over 10 simulations and fit them to the power law g(r) ≈ b · r−m. The parameter m represents the decreasing slope 
of g(r) and b the probability to find a neighbor immune cell, i.e. in direct contact. Figure 8 shows estimates of the 
spatial distribution of immune infiltrates in the lobular epithelium for different damage rates of epithelial cells 
kdge, hormone levels θ and effector killing rates kkill.
Figure 7. Influence of hormone levels on epithelial damage and inflammatory responses. The results are 
averaged over 10 simulations, for every parameter constellation, each consisting in 12 menstrual cycles of 28 
days. The mean (marked solid line) and min/max (shadow) values are represented. (a) Normalized curves of 
epithelial cell proliferation and apoptosis during the menstrual cycle for normal (θ = 1.0), increased (θ = 2.0) 
and decreased (θ = 0.5) hormone levels. (b) Relative number of immune cells for increasing hormone levels 
and different kdge values with kkill = 0.10. (c) Difference between the maximum and minimum relative number of 
regulatory and effector cells, as well as the total amount of immune cells, for kdge = 0.15 and kkill = 0.10. (d,e) Relative 
number of damaged epithelial and immune cells for increasing kdge values and different hormone levels with 
kkill = 0.10, respectively.
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Figure 8a,b shows that in normal breast tissue lobules without epithelial damage, sparse and uniform spatial 
distributions of immune infiltrates are predicted irrespective of the hormone levels. The high and almost invariant 
values of m for increasing hormone levels indicate that immune cells are well distributed in the whole lobular 
epithelium (Fig. 8a). In turn, the low b values evidence that immune cell clusters are rare spatial patterns in normal 
breast tissue (Fig. 8b). On the other hand, model simulations suggest that epithelial damage induces clustering 
patterns of immune cells (Fig. 8a,b). Moreover, immune cell clusters are more frequent for elevated hormone 
levels as indicated by the decreasing m values and the high estimates of b. Figure 8c,d shows that cluster forma-
tion is favoured by high damage rates of epithelial cells kdge and low effector killing rates kkill. Furthermore, model 
analysis reveals that the number of clusters is associated with the degree of epithelial damage and cluster sizes 
with the effectiveness of the immune response. Figure 8e,f shows the power law fittings of some radial distribution 
functions for different parameter combinations.
Figure 9 shows the relative number and spatial distribution of immune cells in a cross-section of a TDLU with 
and without epithelial damage. While immune cells are well distributed in the normal lobular epithelium irre-
spective of the hormonal status (Fig. 9a), clusters emerge broadly distributed for rising damage rates of epithelial 
cells (Fig. 9b). Model simulations predict that clustering patterns of immune cells are most common in the luteal 
phase of the menstrual cycle (Fig. 8). Moreover, we found that cluster formation is a faster process than resolution 
via dispersal of immune cells after killing the damaged epithelial cells. Model results support that immune cells 
are mainly localized in contact or close to epithelial cells, which is predicted to be more pronounced with epithe-
lial damage irrespective of the kkill value (Fig. 10a,b). However, large clusters of immune cells do not necessarily 
imply a more effective clearance of damaged cells, since most of the effectors may not be in direct contact with 
target cells (Fig. 9b).
Epithelial damage results in different inflammatory patterns between TDLUs. We extend the 
model to the investigation of single TDLUs to reflect the heterogeneity of mammary tissue, where focal inflam-
matory changes can be close to unaffected areas. This type of heterogeneity not only in the density and func-
tional orientation of immune infiltrates, but also in the inflammation patterns between close lobular structures, 
is suggested relevant for a more comprehensive picture of the epithelial damage in a realistic clinical context. 
Figure 10c,d shows the time evolution of the relative number of immune cells in different cross-sections of TDLUs 
with and without epithelial damage. We found similar degrees of inflammation between different healthy TDLUs 
irrespective of the menstrual cycle phase (Fig. 10c). However, epithelial damage results in different amounts of 
immune infiltrates across lobular structures in their spatial context, assuming that these neighbours have the same 
intrinsic cell features (Fig. 10d). Although this result is obtained mainly in the luteal phase of the menstrual cycle, 
it can also be observed in the follicular phase. This extends our previous findings in Fig. 9, where we indicated 
that inflammation patterns are spatially heterogeneous within TDLUs for selected time points. Here we show that 
relevant heterogeneity also exists between lobular structures. Therefore, quantifying the degree of inflammation 
in several TDLUs and at distinct time points is predicted to provide a better net estimation of the immunological 
context and breast tissue damage.
Figure 8. Influence of hormone levels and epithelial damage on the spatial distribution of immune cells. 
The results are averaged over 10 simulations for every parameter constellation. The mean (marked solid line) 
and min/max (shadow) fitted values are represented. (a–d) Estimates of parameters m and b of the power law 
b · r−m that better fit the radial distribution functions g(r) at the follicular (day 5) and luteal (day 25) phase of 
the menstrual cycle, as well as in the middle (day 14). (e,f) Radial distribution functions g(r) at day 25 of the 
menstrual cycle for different parameter sets and the resulting power law fittings.
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Shorter menstrual cycles enhance epithelial damage and persistence of inflammation. 
Epidemiologic studies have reported that the luteal phase is consistently 14 days long with only minor variations, 
whereas the duration of the follicular phase usually ranges from 10 to 21 days48. This is largely in line with the 
distribution of total menstrual cycle length (follicular and luteal phases) in the cohort of the patients considered43, 
which varies from 25 to 38 days (Supplemental Table S1). We investigate the role of menstrual cycle length on 
epithelial damage and inflammatory responses by simulating follicular phases of 7, 14 and 21 days, with the luteal 
phase 14 days long. This results in a short, normal and long menstrual cycle of 21, 28 and 35 days, respectively. To 
do that, we dilate and contract the normalized curves of epithelial cell proliferation and apoptosis in the follicular 
phase 0 ≤  t ≤  14, while keeping invariant the curve shapes in the luteal phase (Fig. 11a).
The menstrual cycle length is predicted to be an important factor influencing the inflammation degree. 
Fig. 11b shows that, in general, short menstrual cycles correlate with an increased amount of damaged epithe-
lial cells rather than longer periods. This is due to the major relative contribution of the luteal phase, where the 
probability of epithelial damage is higher because increased cell turnover rates. In general, one could assume that 
a longer follicular phase may give to the body more relaxation time after a phase of intense cell turnover and, as 
a consequence, favoring cytotoxic effector responses. In fact, Fig. 11c shows that short menstrual cycles induce 
stronger inflammations in response to increasing kdge values. Model simulations predict that irrespective of the 
follicular phase length, there exists a critical kdge value for which variations in the amount of immune infiltrates 
in the lobular tissue during the menstrual cycle first increase and then decrease again. Comparing Fig. 11d to 
Fig. 11e, we observe that such variations significantly increase for longer periods. This implies that for high dam-
age rates of epithelial cells, shorter menstrual cycles lead to more severe and persistent inflammatory responses.
Discussion
In this work, we investigated the prognostic potential of inflammatory patterns in non-malignant breast lobular 
tissue in the context of related pathologies. The accurate interpretation of inflammatory patterns observed in 
diagnostic biopsies in the context of breast cancer requires a deeper understanding of the range of normal 
immune cell infiltrations in the course of the menstrual cycle, as well as a better definition of how physiological 
states can be differentiated from potentially pathological conditions such as lymphocytic lobulitis (LLO). To that 
end, we developed an agent-based model of immune and epithelial cell interactions in the breast lobular epi-
thelium under the influence of hormonal changes during the menstrual cycle. Physiological model parameters 
were calibrated on the basis of spatial data extracted from digital whole-slide images of immunohistochemical 
epithelial, vascular and immune cell markers. These images were acquired on clinical annotations from a cohort 
of healthy patients who underwent reduction mammoplasty43. Reduction mammaplasty tissues can be regarded 
Figure 9. Immunological context in cross-sections of a terminal ductal lobular unit (TDLU). Relative 
number and spatial distribution of immune cells for (a) increasing hormone levels θ without epithelial damage 
kdge = 0.0 and (b) increasing kdge values and normal hormone levels θ = 1.0, with kkill = 0.05.
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as the best approximation to the normal state, as close as possible to the physiological situation. The patients 
do not have a specific risk, nor an established cancer, and one can assume a steady state between proliferation 
and apoptosis in the adult irrespective of the breast size. This is confirmed by recent data comparing reduction 
mammoplasty tissues to an exceptional series of small needle biopsies of healthy volunteers, reporting no major 
differences besides a slightly increased incidence of non-malignant “proliferative disease” (focal benign changes 
without cancer risk), but no evidence for disturbed overall cell turnover76. To better align the model parame-
ters with microscopic observations, we used a modular workflow combining a convolutional neural network to 
detect regions of interest with an auto-adaptive random forest pixel-wise classifier to detect nuclei (nucleus con-
tainer module; Definiens, Germany). This analysis of immune cell density and location provided the quantitative 
read-out required as input data of the proposed agent-based model. The immunological context as defined by the 
density, functional orientation and spatial distribution of immune cells, is evidenced to provide valuable informa-
tion beyond currently used descriptive categories to predict potentially pathological scenarios.
Biopsies are single tissue samples typically extracted for a diagnostic purpose, which are by definition always 
performed at a certain time-point that is mostly determined by clinical and organizational needs. In contrast to 
slowly developing pathological changes of epithelial structures, such as benign lesions (e.g. hyperplasia, metaplasia, 
cysts), pre-malignant lesions (e.g. proliferative disease with atypia), and malignant neoplasia (e.g. carcinoma 
in situ or invasive carcinoma), inflammatory changes are prone to temporal variations. Other than stationary 
epithelial lesions, inflammatory patterns are composed of motile cells that can change their relative location, 
differentiation and activation status within few days (or even hours) in response to microenvironmental cues. Our 
approach accounts for this particular situation by introducing a temporal component into the concept of biopsy 
evaluation. In particular, we propose to interpret the snapshot-like single time-point of a tissue sample in the con-
text of a mathematical model representing central aspects of the underlying dynamic processes.
The clinical need for this kind of approach is a consequence of the rapid development of oncoimmunology, 
a therapeutic strategy to target the immune system of cancer patients with immunomodulatory compounds. 
Figure 10. Spatial distribution of immune cells for increasing epithelial damage rates and time evolution of 
immune cells in cross-sections of terminal ductal lobular units (TDLUs). (a,b) The results are averaged over 
10 simulations, for every parameter constellation, each consisting in 12 menstrual cycles of 28 days and normal 
hormone levels. The mean (marked solid line) and min/max (shadow) values are represented. Mean relative 
number of immune cells with respect to their position in the lobular epithelium for (a) kkill = 0.05 and  
(b) kkill = 0.02. (c,d) Simulations of 6 menstrual cycles each of 28 days and normal hormone levels. Relative 
number of immune cells in different TDLUs for (c) kdge = 0.0 and (d) kdge = 0.2, with kkill = 0.02.
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Currently, several such therapies are in clinical testing in breast cancer, as well as in other tumor types. As a 
consequence, immune cell evaluation is shifted into the focus of diagnostic biopsy analysis77. So far, inflamma-
tory changes such as LLO have largely been considered as bystander-effects in breast pathology, and historically 
the main focus of diagnostic evaluation used to be on the epithelial neoplasia78. This is changing dramatically. 
Meanwhile, there is even standardized protocol for immunoscoring in breast cancer79, however, this does not 
yet consider the inflammatory microenvironment of the non-malignant (pre-existing) mammary gland struc-
tures. We expect that immunological responses to the non-malignant epithelium provide valuable information 
on oncogenesis (i.e. the process leading to malignant transformation), and prognosis once a tumor is established. 
In this clinical context, our model predictions hint towards novel criteria for breast biopsy evaluation that allow 
for a more comprehensive analysis and potentially further prognostic parameters in breast cancer pathology. In 
particular, model results suggest that for immune cell evaluation (i) the time-point and eventually the optimal 
frequency of biopsy sampling should be considered, (ii) clinical patient data such as the hormonal status and the 
menstrual cycle phase should be taken into account and (iii) inflammatory events can be heterogeneous, indicat-
ing that the size and number of biopsies should be adjusted to the diagnostic purpose.
A first recommendation is based on the finding that the time point of a biopsy is critical for the density of 
immune infiltrates and inflammatory patterns. Model results suggest that inflammation is an oscillatory phenom-
enon during the menstrual cycle. This predicts that taking a breast biopsy sample at an arbitrary time point of the 
menstrual cycle could lead to wrong conclusions about the mammary gland inflammatory profile. Therefore, we 
propose that requests for breast tissue biopsy evaluation should always include information of the probable cycle 
phase and relevant medication (e.g. anticonception, anti-hormonal therapy, immunosuppressive drugs like cor-
ticosteroids, etc.). Another important result of our study is that changes in hormone levels strongly influence the 
amount of infiltrating lymphocytes present in the breast lobular tissue during the menstrual cycle. This touches 
aspects of a long standing discussion on whether or not oral anticonception can increase the risk of malignancies. 
So far, the stimulatory effects of hormone level modulations on epithelial cell turnover have been in the focus of 
the scientific discussion2,3,14,46,48,80. Model simulations show that the timing of hormonal cycles (e.g. the artificial 
induction of a 28-days-long menstrual cycle by oral anticonceptives), could induce an immunological phenome-
non that potentially could link breast cancer risk to hormonal therapies. Moreover, model results suggest that the 
known effects of the synthetic steroid hormones on increased turnover rate of epithelial cells could be aggravated 
by the artificial limitation of the follicular phases to approximately 14 days. Following this line of reasoning, one 
could consider the variable, sometimes extended follicular phase in natural menstrual cycles as an immunological 
recovery phase. Normalizing or shortening this phase may enhance epithelial cell damage and persistent inflam-
mation responses, hypothetically even leading to an increased risk of developing pre-neoplastic lesions.
As stated above, we found out that the density, functional orientation and spatial distribution of immune cells 
provide valuable information for the prediction of potential pathological scenarios. These immune-related fea-
tures can be, for instance, extrapolated from digital whole-slide images of immunohistochemical epithelial and 
immune cell markers by image analysis processing. Immune infiltrate density, within lobular structures, is con-
sidered as the traditional diagnostic criterion, since high concentration of lymphocytes suggests pathological con-
ditions. However, model simulations suggest that just an increased infiltrate density is not enough to distinguish 
Figure 11. Influence of menstrual cycle length on epithelial damage and inflammatory responses. The 
results are averaged over 10 simulations, for every parameter constellation, each consisting in 12 menstrual 
cycles and normal hormone levels. (a) Normalized curves of epithelial cell proliferation and apoptosis for 
menstrual cycles with the follicular phase of 7, 14 and 21 days, with the luteal phase 14 days long. (b,c) Mean 
relative number of damaged epithelial and immune cells in the short and long menstrual cycle for increasing kdge 
values. (d,e) Difference between the maximum and minimum relative number of regulatory and effector cells, 
as well as the total amount of immune cells, in the short and long menstrual cycle for increasing kdge values.
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a severe, but periodically resolving from a chronic potentially persisting, and a chronic (persistent) inflamma-
tory response. The next feature of interest would be the functional orientation of immune cells, that could be 
captured for example in the form of differences in the balance between effector and regulatory cell populations. 
Even though highly immunosuppressive microenvironment in breast lobular areas, hypothetically represented 
by a greater difference, should suggest chronic inflammations, intermediate values are probably not conclusive. 
Further in-depth studies including more detailed sub-typing of immune cells are required to clarify those ques-
tions. We realize that our model is working under the greatly simplified assumption that all detected regulatory 
cells are equally promoting a suppressing T-effector cell function. While this is a reasonable simplification 
for physiological situations, we will need to diversify the range of regulatory agents for applications modeling 
pathological conditions such as tumors or their precursor lesions. In addition, we propose to characterize the 
spatial distribution of immune cells in terms of lymphocyte clustering formation. According to our in silico 
results, in the case of an unusually high amount of immune infiltrates, intense immunosuppression and a large 
number of clusters can safely suggest that lobular inflammation is pathological, and further clinical actions 
need to be taken. Figure 12a summarizes the model-driven proposal for immunological context evaluation in 
breast lobular tissue.
As a proof of principle, we compare small cohorts of breast tissue samples from women who underwent (i) 
reduction mammoplasty (RM) and (ii) prophylactic mastectomy (PM) due to an increased risk for hereditary 
breast cancer (BRCA1/2 mutations), as well as (iii) normal lobular tissue adjacent to neoplastic tissue (NT) 
from women with clinically manifest breast cancer. In this order, the afore-mentioned categories typically 
exhibit increased rates of epithelial damaged, e.g. potentially as a result of increasingly accumulated germ line 
aberrations. This additional experimental data supports the model predictions of increased amount of infil-
trating immune cells, both effector and regulatory cells (Fig. 12b), as well as more immune infiltrates localized 
in contact and close to lobular epithelium (Supplemental Fig. S12), for increasing epithelial damage rates. 
Additionally, we observe that epithelial damage induces higher variations in the amount of immune infiltrates 
as suggested by the model simulations. An improved characterization of immune infiltrate spatial patterns in 
larger cohorts of normal and neoplastic tissue samples, integrating relevant personalized clinical data, will be 
the subject of future work.
Figure 12. Model-driven diagnostic criteria. (a) Immunological evaluation in breast lobular tissue with 
respect to immune cell density, functional orientation and spatial distribution. (b) Quantification of immune 
cells in breast lobular tissue from women who underwent reduction mammoplasty (RM) due to orthopedic or 
cosmetic reasons, and prophylactic mastectomy (PM) due to BRCA1/2 mutations. Amount of immune cells 
in normal lobular tissue adjacent (more than 1 mm) to breast cancer/neoplastic tissue (NT) is also quantified. 
From top to bottom, the relative number of CD8+, CD163+ and CD4+ cells with respect to epithelial cells. Each 
box is drawn around the region between the first and third quartiles of the data points, with a horizontal line at 
the median value and whiskers extend for a range equal to 1.5 times the interquartile range.
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In summary, the model analysis provided a better understanding of the role of inflammation in breast lobular 
epithelium, emphasized the prognostic value of the menstrual cycle length and hormone levels, and linked spatial 
distributions of immune infiltrates to potentially pathological scenarios. Although the biological processes involved 
and the immunological landscape are expected to be much more complicated than the current model description, 
we believe that our findings and the proposed modeling framework are important steps forward towards 
extended, more comprehensive criteria for breast tissue biopsy evaluation, specifically supporting the devel-
opment of novel prognostic markers, and companion biomarkers guiding for immunomodulatory therapeutic 
interventions.
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